RxDoctor Payments Data

Alisa Orr

Adult Health · Idaho Falls, IDNPI 1851988265

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.3% of the total across 542 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,969, 2.7 times the $1,091 reported in 2021. Among adult health clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,459in general payments, 2019–2025

Across 542 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$938
  • Novartis$749
  • Johnson & Johnson$733
  • Pfizer$663
  • Daiichi Sankyo Inc.$564
  • Merck$533
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$10,06896%
  • Education$3914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca42$938
Novartis48$749
Johnson & Johnson38$733
Pfizer52$663
Daiichi Sankyo Inc.30$564
Merck26$533
AbbVie19$378
Sanofi22$368
Genentech USA, Inc.21$350
Myriad Genetic Laboratories, Inc.4$308
Takeda Pharmaceuticals U.S.A., Inc.13$296
Bristol Myers Squibb15$294
Eisai Inc.14$294
Amgen16$273
Lilly USA, LLC14$252
Tersera Therapeutics LLC12$222
AVEO Pharmaceuticals, Inc.3$205
Astellas Pharma US Inc10$175
Seagen Inc.11$172
Sobi, Inc9$165
GSK9$158
Dendreon Pharmaceuticals LLC7$153
Pharmacyclics LLC, An Abbvie Company3$146
Puma Biotechnology, Inc.7$138
Beigene USA, Inc.6$129
Servier Pharmaceuticals LLC6$121
Jazz Pharmaceuticals Inc.4$106
E.r. Squibb & Sons, L.L.C.4$103
Incyte Corporation6$100
Genmab U.S., Inc.5$95
Regeneron Healthcare Solutions, Inc.5$93
Beone Medicines USA, Inc.3$90
Stemline Therapeutics Inc.4$87
EMD Serono, Inc.5$79
Bayer4$69
Iovance Biotherapeutics, Inc.3$60
Deciphera Pharmaceuticals Inc.3$54
Boehringer Ingelheim2$51
Geron Corporation2$51
Coherus Oncology, Inc.2$49
Array Biopharma Inc3$43
Karyopharm Therapeutics Inc.2$42
Medtronic2$40
EUSA Pharma (US) LLC2$39
Spectrum Pharmaceuticals Inc.2$36
Rigel Pharmaceuticals, Inc.1$33
Legend Biotech USA Inc.1$33
Pharmacosmos Therapeutics Inc.2$33
Fresenius Kabi USA, LLC2$30
Blueprint Medicines Corporation2$30
G1 Therapeutics, Inc.2$28
Pharmaessentia USA Corporation1$23
Syndax Pharmaceuticals, Inc.1$22
Novocure Inc.1$22
Springworks Therapeutics, Inc.1$20
ADC Therapeutics America, Inc.1$20
Exelixis Inc.1$19
Agios Pharmaceuticals, Inc.1$18
Mirati Therapeutics, Inc.1$18
Organon2$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,459 in reported general payments places this provider in the 95th percentile of 38 adult health providers in Idaho.

See all adult health providers in Idaho

Medicare billing

Part B allowed, 2024
$45,064
Medicare patients
280
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$23,132
Ondansetron Hcl29$5,364
Colesevelam Hcl12$3,017
Potassium Chloride49$920
Hydroxyurea27$782
Letrozole45$772
Gabapentin39$694
Tamoxifen Citrate22$553
Dexamethasone14$506
ValacyclovirValacyclovir Hcl12$392
Warfarin Sodium70$342
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$186
Prednisone17$185
Oxycodone Hcl11$175
Levothyroxine Sodium12$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$663$23,13232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 adult health providers in Idaho.

Other adult health in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →